Rising R&D Activities through Company Collaborations
With rising investment cost of R&D and cost of further manufacture of drugs, several large-, medium- and small-sized biotech and pharma companies come together for a collaborative partnership with larger firms. Usually, small companies have good R&D facilities but do not have sufficient capital for conducting global, multicenter, and large-scale clinical trials. Most of them out-license their products after early clinical development phase. For example, in the past, GlaxoSmithKline collaborated with Anacor Pharmaceuticals for development and commercialization of antibacterial and anti-viral drugs. Recently, Shionogi & Co. Ltd collaborated with F. Hoffmann-La Roche Ltd for a siderophore cephalosporin development. This is one of the major factors for the growth of the cephalosporin drugs market.
Other factors, such as rising demand of anti-microbial for various diseases, rising prevalence of infectious diseases and use of combination therapies are some of the primary factors for the growth of this market.
Stringent Regulatory Guidelines
There are several regulatory aspects involved in the pharmaceutical industries, along with the complexity of the market, which affects their growth in the market. Several companies are not able to pass through the stringent bioequivalence testing for checking the therapeutic potential and toxicity levels. In the past decade, several APAC countries tightened their monitoring and inspection of imported antibiotics with more stringent requirements for their testing, such as Japan pharmaceutical and Medical Devices Agency and Korean FDA. Another factor is the low number of molecules in the pipeline, which is hindering the growth of the cephalosporin drugs market.
Asia-Pacific to Dominate the Market
The cephalosporin drugs market is segmented by generation, route of administration, drug, and geography. By geography, it is segmented into North America, Europe, Asia-Pacific, Middle East & Africa (MEA), and South America.
Asia-Pacific is expected to dominate this market due to high prevalence of infectious diseases, increasing healthcare expenditure, and large population base. Further, the demand for better healthcare infrastructure and government initiatives are expected to help growth in this region. Asia-Pacific is followed by Europe, due to its large base of geriatric population and rising prevalence of infectious diseases in several countries of the region.
Key Developments in the Market
- February 2018: AGP Limited aimed to boost the capacity of its cephalosporin plant, to support the increasing demand for its primary products and establish the facilities for neutraceuticals.
- February 2018: Allergan is developing combination aztreonam and avibactam for gram-negative infections, which restores the antibacterial activity to cephalosporin.
Reasons to Purchase the Report
- Current and future of the global cephalosporin drugs market outlook in the developed and emerging markets
- Analyzing various perspectives of the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3 month analyst support, along with the Market Estimate sheet (in Excel)
This report can be customized to meet your requirements.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rising Demand for Anti-microbials in Various Indications
6.1.2 Rising R&D Activities through Company Collaborations
6.1.3 Rising Prevalence of Infectious Diseases
6.1.4 Increasing Use of Combination Therapies
6.2 Market Restraints
6.2.1 Stringent Regulatory Guidelines
6.2.2 Weak Pipeline Molecules
6.4 Key Challenges
7. Market Segmentation
7.1 By Generation
7.2 By Route of Adminstration
7.3 By Type of Drug
7.4 By Geography
7.4.1 North America
220.127.116.11 United States
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
7.4.4 Middle East & Africa
184.108.40.206 South Africa
220.127.116.11 Rest of the Middle East & Africa
7.4.5 South America
18.104.22.168 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.2 Astellas Pharma Inc.
9.3 Baxter International
9.4 Bristol-Myers Squibb Company
9.5 GlaxoSmithKline PLC
9.6 Lupin Pharmaceuticals
9.7 Merck & Co. Inc.
9.8 Pfizer Inc.
9.9 Roche Holding AG
9.10 Teva Pharmaceuticals
9.11 List Not Exhaustive
10. Future of the Market